相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
John J. V. McMurray et al.
EUROPEAN HEART JOURNAL (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
Mariam Alatrach et al.
DIABETES (2020)
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
Jagdeep S. S. Singh et al.
DIABETES CARE (2020)
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
David Z. Cherney et al.
DIABETOLOGIA (2020)
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
Alexander J. M. Brown et al.
EUROPEAN HEART JOURNAL (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SGLT2 Inhibitor Induced Sympathoinhibition A Novel Mechanism for Cardiorenal Protection
Lakshini Y. Herat et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia/reperfusion injury
Zhao Li et al.
CARDIOVASCULAR RESEARCH (2019)
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
Tadashi Toyama et al.
DIABETES OBESITY & METABOLISM (2019)
Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
Ting-I Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study
Axel Akerblom et al.
UPSALA JOURNAL OF MEDICAL SCIENCES (2019)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2018)
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
Mikhail Kosiborod et al.
DIABETES OBESITY & METABOLISM (2018)
Heart failure with preserved ejection fraction: from mechanisms to therapies
Carolyn S. P. Lam et al.
EUROPEAN HEART JOURNAL (2018)
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
Franco Cosmi et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
Mikhail Kosiborod et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Metabolites as regulators of insulin sensitivity and metabolism
Qin Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
Laween Uthman et al.
FRONTIERS IN PHYSIOLOGY (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes
Julian Mustroph et al.
ESC HEART FAILURE (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Sacubitril/valsartan: beyond natriuretic peptides
Jagdeep S. S. Singh et al.
HEART (2017)
Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction 5-Year Outcomes
Kevin S. Shah et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
Ioanna Andreadou et al.
FRONTIERS IN PHYSIOLOGY (2017)
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Bart Staels
AMERICAN JOURNAL OF MEDICINE (2017)
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
Nadjib Hammoudi et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
Jagdeep S. S. Singh et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
SGLT2 Inhibitors and the Diabetic Kidney
Paola Fioretto et al.
DIABETES CARE (2016)
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside
Sunder Mudaliar et al.
DIABETES CARE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?
David Z. I. Cherney et al.
CANADIAN JOURNAL OF DIABETES (2014)
Erythropoietin and the heart: Physiological effects and the therapeutic perspective
Fabian Sanchis-Gomar et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Forecasting the Impact of Heart Failure in the United States A Policy Statement From the American Heart Association
Paul A. Heidenreich et al.
CIRCULATION-HEART FAILURE (2013)
Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology
Richard M. Cubbon et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Intracellular Na+ and cardiac metabolism
Johannes Bay et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
Karl Swedberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle
Lauren Aerni-Flessner et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41)
Ikuo Kimura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study
Charlotte Andersson et al.
EUROPEAN JOURNAL OF HEART FAILURE (2010)
Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction A Meta-Analytic Approach
Daniel G. Kramer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Evidence for a Causal Role of Oxidative Stress in the Myocardial Complications of Insulin Resistance
Rebecca H. Ritchie
HEART LUNG AND CIRCULATION (2009)
Cardiorenal Syndrome
Claudio Ronco et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database
J. Thomas Heywood et al.
JOURNAL OF CARDIAC FAILURE (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
John G. F. Cleland et al.
EUROPEAN HEART JOURNAL (2006)
Erythropoietin in cardiovascular diseases
P van der Meer et al.
EUROPEAN HEART JOURNAL (2004)
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
AH Barnett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Diastolic heart failure - Abnormalities in active relaxation and passive stiffness of the left ventricle
MR Zile et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure
BA Groenning et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
分享论文
